<DOC>
	<DOCNO>NCT01885104</DOCNO>
	<brief_summary>The purpose study compare safety tolerability oral ingestion PEG 3350 solution concentrate oral ingestion placebo solution concentrate , participant constipation .</brief_summary>
	<brief_title>Safety Tolerability Oral Polyethylene Glycol ( PEG 3350 ) Solution Participants With Constipation ( MK-8114-003 )</brief_title>
	<detailed_description>This randomize , single-blind , placebo-controlled study evaluate proportion participant abnormalities oral mucosa detect visual examination oral cavity polyethylene glycol ( PEG ) 3350 group compare placebo group . The study also evaluate proportion participant abnormality esophageal mucosa detect endoscopic examination esophagus PEG 3350 group compare placebo group , compare safety tolerability evaluation proportion participant occurrence adverse event ( AEs ) adverse drug reaction .</detailed_description>
	<mesh_term>Constipation</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Bisacodyl</mesh_term>
	<mesh_term>Cathartics</mesh_term>
	<mesh_term>Laxatives</mesh_term>
	<mesh_term>Polyethylene glycol 3350</mesh_term>
	<criteria>ambulatory male female history current evidence condition abnormality would affect study result interfere participation full duration study meet diagnostic criterion functional constipation . This include loose stool rarely present without use laxatives 2 following : strain least 25 % defecation ; lumpy hard stool least 25 % defecation ; sensation incomplete evacuation least 25 % defecation ; sensation anorectal obstruction/blockage least 25 % defecation ; manual maneuver facilitate least 25 % defecation [ e.g. , digital evacuation , support pelvic floor ] ; few 3 defecation per week . Criteria functional constipation must fulfil last 3 month , symptom onset least 6 month prior diagnosis . continuous recurrent symptom least 3 month : abdominal pain discomfort , relieve defecation , associate change frequency consistency stool , irregular pattern defecation least 25 % time 3 following : altered stool frequency , alter stool form ( hard loose/watery ) , alter stool passage ( strain urgency , feel incomplete evacuation ) , passage mucus , bloat abdominal distension agree use laxative study medication duration study period agree use disallow concomitant medication duration study agree maintain similar diet level activity period Screening Visit End Study individual reproductive potential must agree remain abstinent use ( partner use ) 2 acceptable method birth control 2 week last dose study drug last treatment period . Acceptable method birth control include : intrauterine device ( IUD ) , diaphragm spermicide , contraceptive sponge , condom , vasectomy . abnormal baseline endoscopy and/or oral exam baseline oral exam show evidence oral lesion , herpes labialis aphthous stomatitis , know selfreported history current periodontal gum disease history impair swallow difficulty swallow food liquid know , history , suspect gastrointenstinal disease , include bowel perforation , obstruction , fecal impaction ; irritable bowel syndrome ( IBS ) , delay gastric empty , gastroparesis , gastroesophageal reflux disease ( GERD ) , gastritis peptic ulcer disease ( PUD ) , dehydration , inflammatory bowel disease , bowel resection , anal fistulas/fissures , colostomy , etc . severe unexplained abdominal pain history current alcohol drug abuse history malignancy â‰¤5 year prior sign inform consent , except adequately treat basal cell and/or squamous cell skin cancer situ cervical cancer history psychiatric illness require medication hospitalization within previous 12 month history concurrent illness require hospitalization within 4 week prior Day 1 study allergy allergic reaction intolerance product use study degree renal impairment major surgery clinically significant illness within 4 week prior Day 1 Visit 1 current recent ( within past 30 day sign informed consent ) participation study investigational compound device refusal agree donate egg sperm upon first study drug administration thereafter 90 day last study drug administration individual employee family member employee sponsor clinical unit study conduct</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>